Search Results - "DeFRIESS, N."

Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs by Agersø, H., Stennicke, H. R., Pelzer, H., Olsen, E. N., Merricks, E. P., deFriess, N. A., Nichols, T. C., Ezban, M.

“…Summary The objective of the present study was to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the new recombinant FVIII compound…”
Get full text

Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs by KARPF, D. M., KJALKE, M., THIM, L., AGERSØ, H., MERRICKS, E. P., DEFRIESS, N., NICHOLS, T. C., EZBAN, M.

“…N8, a new recombinant factor VIII (rFVIII) compound developed for the treatment of haemophilia A, is produced in Chinese hamster ovary (CHO) cells and…”
Get full text

Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B by NICHOLS, T. C., RAYMER, R. A., FRANCK, H. W. G., MERRICKS, E. P., BELLINGER, D. A., DeFRIESS, N., MARGARITIS, P., ARRUDA, V. R., KAY, M. A., HIGH, K. A.

“…Dogs with haemophilia A or haemophilia B exhibit spontaneous bleeding comparable with the spontaneous bleeding phenotype that occurs in humans with severe…”
Get full text